Patent information fails to hold the stock price. Production information is important to the forward direction of the company but it is insignificant in turms of bolstering and holding up the SP. These types of NRs speak for themselves otherwise we would not be scraping .60 and .70 cents.

All the NRs are an important part of the Alda journey, but at the end of the day the volume and SP is what is mostly important to me and most other investors, even the LT player. If you could place a value on all the NRs I call insignificant, then you would have to expect the stock to be trading between 1.00 - 1.20.

If the DIN (Drug Information Number) is all that holds us back from branding and retail, I agree it would be full scale ahead. However, unless you have inside information, this is only a quess. I am suggesting if the DIN came out this week, we would gap up but without the ensuing branding and retail information, the gap would be short lived - the shorters love this stock.